Literature DB >> 23632240

Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma.

Myung Su Son1, Moon Ju Jang, Young Joo Jeon, Won Hee Kim, Chang-Il Kwon, Kwang Hyun Ko, Pil Won Park, Sung Pyo Hong, Kyu Sung Rim, Sung Won Kwon, Seong Gyu Hwang, Nam Keun Kim.   

Abstract

BACKGROUND: Numerous studies have focused on the association between miR-34 family members, which are direct p53 targets, and carcinogenesis of many cancers, including hepatocellular carcinoma (HCC). This study aimed to assess whether polymorphisms in the single-nucleotide polymorphism miR-34b/c T>C (rs4938723) and TP53 Arg72Pro (rs1042522) increase the risk of HCC and influence outcome in patients with HCC. PATIENTS AND METHODS: We enrolled 157 HCC patients and 201 cancer-free control subjects from the Korean population. MicroRNA polymorphisms were genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
RESULTS: We found that the miR-34b/c TC+CC frequency was significantly higher in HCC patients than in controls (adjusted odds ratio [AOR]: 1.580; 95% confidence interval [CI]: 1.029-2.426). The miR-34b/c CC-TP53 Arg/Arg combination significantly increased the risk of HCC (AOR: 13.644; 95% CI: 1.451-128.301). The SNPs miR-34b/c T>C and TP53 Arg72Pro(G>C) had no influence on survival of HCC patients.
CONCLUSIONS: Our findings suggest that loss of the T allele in miR-34b/c T>C, and the miR-34b/c CC-TP53 Arg/Arg combination increases the risk of HCC in the Korean population.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23632240     DOI: 10.1016/j.gene.2013.04.042

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  27 in total

1.  Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma.

Authors:  Yue-Li Nan; Yan-Ling Hu; Zhi-Ke Liu; Fang-Fang Duan; Yang Xu; Shu Li; Ting Li; Da-Fang Chen; Xiao-Yun Zeng
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population.

Authors:  Chun-Jia Liu; Xue-Wei Ma; Xue-Jun Zhang; Shi-Qiang Shen
Journal:  Int J Mol Epidemiol Genet       Date:  2017-02-15

Review 3.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

4.  Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.

Authors:  Moqin Qiu; Yingchun Liu; Xiangyuan Yu; Linyuan Qin; Chunhua Bei; Xiaoyun Zeng; Xiaoqiang Qiu; Bo Tang; Songqing He; Hongping Yu
Journal:  Tumour Biol       Date:  2015-10-17

5.  Association Between Polymorphisms in the Promoter Region of microRNA-34b/c and the Chemoradiotherapy Efficacy for Locally Advanced Esophageal Squamous Cell Carcinoma in Chinese Han Population.

Authors:  Jilisihan Bulibu; Wei Wang; Yong Tang; Na Li; Keyoumu Saifuding
Journal:  Pathol Oncol Res       Date:  2017-12-21       Impact factor: 3.201

6.  The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.

Authors:  Surong Hu; Lianying Zhao; Jingting Yang; Miao Hu
Journal:  Tumour Biol       Date:  2013-12-11

7.  Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.

Authors:  Fang Yuan; Ruifen Sun; Peng Chen; Yundan Liang; Shanshan Ni; Yi Quan; Juan Huang; Lin Zhang; Linbo Gao
Journal:  Tumour Biol       Date:  2015-11-30

8.  Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk.

Authors:  Sara Sanaei; Mohammad Hashemi; Maryam Rezaei; Seyed Mehdi Hashemi; Gholamreza Bahari; Saeid Ghavami
Journal:  Biomed Rep       Date:  2016-05-23

9.  Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls.

Authors:  Tao Tao; Shuqiu Chen; Bin Xu; Chunhui Liu; Yiduo Wang; Yeqing Huang; Ming Chen
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

10.  Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data.

Authors:  De-Hui Yi; Ben-Gang Wang; Xin-Ping Zhong; Hao Liu; Yong-Feng Liu
Journal:  Tumour Biol       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.